US Point-of-Care Molecular Diagnostics Market (2025-2030)
The US Point-of-Care Molecular Diagnostics Market was valued at $1070.4 Million in 2025 and projected to reach to $1786 Million by 2030, representing a compound annual growth rate of 10.8%. The US Point-of-Care Molecular Diagnostics Market is poised for substantial growth through 2030, driven by healthcare providers' increasing preference for rapid, accurate diagnostic solutions that reduce time-to-treatment.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Point-of-Care Molecular Diagnostics Market Trends and Insights
- The US market is driven by increasing demand for rapid diagnostic solutions in clinical settings, urgent care facilities, and decentralized healthcare environments.
- In 2025, the US represents a significant portion of North American diagnostics innovation, with healthcare providers prioritizing faster turnaround times and improved patient outcomes. By 2030, the US market will continue to benefit from technological advancements in molecular testing platforms and growing adoption of point-of-care solutions across diverse healthcare settings.
- The US regulatory environment and reimbursement landscape support the expansion of these diagnostic tools, enabling broader accessibility in both urban and rural regions.
- Investments in healthcare infrastructure and the shift toward personalized medicine further accelerate market penetration across the US..
Key Market Statistics
- CAGR (2025-2030) 10.8% CAGR
- Market Size, 2025 ~USD 1070.4 Million
- Forecast, 2030 ~USD 1786 Million
- Country US
US Point-of-Care Molecular Diagnostics Market Overview
Market Valuation :
The US Point-of-Care Molecular Diagnostics Market is valued at $1,070.4 million in 2025, with strong growth trajectory positioning it as a key segment within American healthcare diagnostics.
Robust Growth Rate :
The US market is expanding at a CAGR of 10.8% from 2025 to 2030, outpacing the global growth rate of 10.5%, indicating accelerating adoption within the United States healthcare system.
Decentralized Healthcare Adoption :
Increasing demand for rapid diagnostic solutions across urgent care facilities, clinical settings, and decentralized healthcare environments is driving significant market expansion throughout the US.
Projected Market Size :
The US market is forecasted to reach $1,786.0 million by 2030, representing a growth of approximately $715.6 million over the five-year period, reflecting strong market confidence and investment.
US Point-of-Care Molecular Diagnostics Market Dynamics
- The shift toward decentralized healthcare delivery, coupled with rising demand in urgent care and emergency departments, creates significant opportunities for market expansion.
- Technological advancements and regulatory support for point-of-care testing further accelerate adoption across diverse clinical settings. Key growth drivers include the aging US population, rising prevalence of infectious diseases, and healthcare systems' focus on operational efficiency.
- Investment in healthcare infrastructure and the integration of molecular diagnostics into routine clinical workflows will continue to propel market growth.
- The competitive landscape is intensifying as major diagnostics companies expand their point-of-care portfolios, ensuring continued innovation and market dynamism through 2030..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- The US Point-of-Care Molecular Diagnostics Market is valued at $1,070.4 million in 2025 and will reach $1,786.0 million by 2030, growing at a 10.8% CAGR.
- The US market is driven by demand for rapid diagnostic solutions in clinical and urgent care settings, with healthcare providers prioritizing faster turnaround times.
- The US regulatory environment and reimbursement policies support broader adoption of point-of-care molecular diagnostics across diverse healthcare settings.
- By 2030, the US market will benefit from technological advancements and the shift toward decentralized, personalized medicine in both urban and rural regions.
Point-of-Care Molecular Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SEPSIS (Disease Type) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 10.5% from 2025 to 2030 |
| Largest Segment | RT-PCR (Technology) |
| Market Size Base Year (Billions) | ~USD 4.3 (2025) |
| Revenue Forecast (Billions) | ~USD 7.09 (2030) |
| Segments Covered | Product & Service, Technology, Sample Type, Application, End User, Disease Type |
US Point-of-Care Molecular Diagnostics Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Assays & Kits
- Instruments & Analyzers
- Software & Services
By Technology
- Inaat
- Other Technologies
- Rt-Pcr
By Sample Type
- Blood Samples
- Other Sample Types
- Urine Samples
By Application
- Cancer
- Gastrointestinal Disorders
- Hepatitis
- Hospital-Acquired Infections
- Other Applications
- Respiratory Diseases
- Sexually Transmitted Diseases
By End User
- Hospitals
- Other End Users
- Physicians' Offices/Clinics
- Research Institutes
By Disease Type
- Gastroenteritis
- Meningoencephalitis
- Other Diseases
- Sepsis
US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 679.7 | 726.3 | 781.8 | 850 | 934.1 | 1036.6 | 1159.5 | 1310.7 | 10.9 |
| OTHER END USERS | 202.2 | 210.4 | 220.5 | 233.4 | 249.7 | 269.8 | 293.8 | 323.4 | 8 |
| PHYSICIANS' OFFICES/CLINICS | 572.1 | 605.2 | 644.8 | 693.7 | 754.1 | 827.5 | 915.1 | 1022.2 | 9.7 |
| RESEARCH INSTITUTES | 62.4 | 63.9 | 66 | 68.8 | 72.6 | 77.2 | 82.9 | 89.9 | 6.4 |
| TOTAL | 1516.3 | 1605.9 | 1713 | 1845.9 | 2010.5 | 2211.1 | 2451.3 | 2746.2 | 9.9 |
Target Audience
- Diagnostic Equipment Manufacturers : US-based and international manufacturers need market sizing and growth forecasts to guide product development, market entry strategies, and sales projections for point-of-care molecular diagnostic devices.
- Healthcare Providers & Hospital Systems : US hospitals, urgent care centers, and clinical laboratories require market intelligence to justify capital investments in point-of-care molecular diagnostics infrastructure and technology upgrades.
- Investment & Private Equity Firms : Investors evaluating opportunities in US healthcare diagnostics need validated market data, growth rates, and forecasts to assess portfolio companies and identify acquisition targets in this expanding sector.
- Healthcare Consultants & Advisors : Management consulting firms and healthcare advisors serving US clients require accurate market data to develop strategies, conduct competitive analyses, and support client decision-making in diagnostics.
- Regulatory & Policy Organizations : US regulatory bodies, healthcare policy makers, and industry associations need market insights to inform reimbursement policies, regulatory frameworks, and healthcare delivery standards for point-of-care testing.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise US market valuation ($1,070.4M in 2025) and verified CAGR of 10.8% to support strategic planning, investment decisions, and competitive positioning in the American diagnostics sector.
- US-Specific Market Dynamics : Gain deep insights into US-driven demand factors including decentralized healthcare adoption, urgent care expansion, and clinical setting preferences that differentiate the American market from global trends.
- Competitive Intelligence : Understand the US competitive landscape, market consolidation patterns, and growth opportunities specific to American healthcare providers, hospitals, and diagnostic companies operating in this segment.
- Forecast Accuracy for US Operations : Access reliable 2030 projections ($1,786M) tailored to US market conditions, enabling accurate revenue forecasting, resource allocation, and long-term strategic planning for US-focused businesses.
- Regulatory & Implementation Insights : Understand US-specific regulatory environment, reimbursement landscape, and implementation barriers affecting point-of-care molecular diagnostics adoption across American healthcare facilities.
Frequently asked questions
What is the current size of the US Point-of-Care Molecular Diagnostics Market?
The US Point-of-Care Molecular Diagnostics Market is valued at $1,070.4 million in 2025.
What is the projected market size for the US by 2030?
The US market is projected to reach $1,786.0 million by 2030, representing a 10.8% compound annual growth rate.
What are the primary drivers of growth in the US market?
Key drivers include increasing demand for rapid diagnostic solutions, adoption in clinical and urgent care settings, favorable regulatory policies, and the shift toward decentralized healthcare and personalized medicine.
How does the US market compare to the global Point-of-Care Molecular Diagnostics Market?
The US market grows at 10.8% CAGR, slightly outpacing the global CAGR of 10.5%, reflecting strong healthcare infrastructure and innovation adoption in the US.
Which healthcare settings are driving adoption in the US?
Clinical laboratories, urgent care facilities, emergency departments, and decentralized healthcare environments are primary drivers of point-of-care molecular diagnostics adoption in the US.
RESEARCH METHODOLOGY
The study involved estimating activities to determine the current size of the point-of-care molecular diagnostics market. Exhaustive secondary research was done to collect information on the point-of-care molecular diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the point-of-care molecular diagnostics market.
Secondary Research
In the secondary research process, various secondary sources, such as annual reports, press releases, and investor presentations of companies; white papers; certified publications; articles by recognized authors; gold-standard & silver-standard websites; regulatory bodies; and databases like D&B Hoovers, Bloomberg Business, and Factiva, were referred to identify and collect information for this study.
Primary Research
In the primary research process, primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Breakdown of Primaries
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both bottom-up and top-down approaches were used to estimate and validate the point-of-care molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in tkehe mart. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the point-of-care molecular diagnostics market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Point-of-care molecular diagnostics includes various portable point-of-care devices and assays used by healthcare professionals to detect and diagnose diseases in humans using different techniques to identify and analyze nucleic acids or proteins at the molecular level.
Stakeholders
- Manufacturers and distributors of point-of-care molecular diagnostics products
- Physicians’ offices
- Hospitals and clinics
- Research institutes
- Point-of-care molecular diagnostics service providers
- Government associations
- Venture capitalists and investors
Report Objectives
- To define, describe, segment, and forecast the point-of-care molecular diagnostics market by product & service, technology, sample type, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as acquisitions, expansions, product launches & approvals, and other developments in the point-of-care molecular diagnostics market
- To benchmark players within the point-of-care molecular diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full Point-of-Care Molecular Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Point-of-Care Molecular Diagnostics Market.
- Canada Point-of-Care Molecular Diagnostics Market
- Germany Point-of-Care Molecular Diagnostics Market
- UK Point-of-Care Molecular Diagnostics Market
- France Point-of-Care Molecular Diagnostics Market
- Italy Point-of-Care Molecular Diagnostics Market
- Spain Point-of-Care Molecular Diagnostics Market
- China Point-of-Care Molecular Diagnostics Market
- Japan Point-of-Care Molecular Diagnostics Market
- India Point-of-Care Molecular Diagnostics Market
- Brazil Point-of-Care Molecular Diagnostics Market
- Mexico Point-of-Care Molecular Diagnostics Market
- Rest Of Europe Point-of-Care Molecular Diagnostics Market
- Rest Of Asia Pacific Point-of-Care Molecular Diagnostics Market
- Rest Of Latin America Point-of-Care Molecular Diagnostics Market
- Ksa Point-of-Care Molecular Diagnostics Market
- UAE Point-of-Care Molecular Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
